Share Icon Health Study Area: Cardiovascular Disease Chevron Icon Health Study Area: Genitourinary For Patients Health Study Area: Lung Cancer Page Icon Phone Icon For Caregivers Health Study Area: AutoImmune Disease Health Study Area: Melanoma Location Icon Print YouTube Icon For Parents Health Study Area: Lung Cancer Print Created with Sketch. Help Icon Green Check Icon Search Icon Instagram Created with sketchtool. Direction Arrow Icon Error Icon For Parents Health Study Area: Blood Cancer Help Icon Health Study Area: NASH Gender Both Bookmark Icon Health Study Area: Melanoma Created with Sketch. Glossary Print Health Study Area: Blood Cancer Health Study Area: Genitourinary Health Study Area: Gastrointestinal Cancer Mobile Menu Icon Created with Sketch. Health Study Area: Cardiovascular Disease Health Study Area: Women's Cancer Communities Map Icon Created with Sketch. For Caregivers Health Study Area: Fibrosis Health Study Area: AutoImmune Disease FAQs Health Study Area: Head and Neck Cancer Created with Sketch. For Clinicians Chevron Right Icon Gender Female Health Study Area: Breast Cancer Direction Arrow Icon Gender Both Right Arrow Icon LinkedIn Icon Green Check Icon Gender Male Health Study Area: Fibrosis For Patients Twitter Icon Email Icon Facebook Icon Health Study Area: Gastrointestinal Cancer Health Study Area: Head and Neck Cancer For Clinicians External Link Icon
Søg Study Connect

Active, Not Recruiting

Study to Evaluate the Safety and Tolerability of CC-92328 in Participants With Relapsed and/or Refractory Multiple Myeloma - CC-92328-MM-001

Opdateret: 13 februar, 2024   |   ClinicalTrials.gov

Celgene er et helejet datterselskab af Bristol-Myers Squibb 

Udskriftsvenligt sammendrag

OVERVEJER DU DETTE FORSØG?
Udskriv denne side og forsøgsvejledningen som en hjælp til at tale med din læge.
Brug vejledningen til forsøgsdeltagere for at finde rundt i processen for deltagelse i et klinisk forsøg. Forstå de vigtigste faktorer, der skal overvejes, før du beslutter dig, og find spørgsmål, du kan stille dit sundhedsteam.

Forsøgsdetaljer

  • Phase 1

    Fase

  • Køn

  • 18+

    Aldersinterval

  • Active, Not Recruiting

Behandlingsmuligheder

Forsøgsgrene
TILDELT INTERVENTION
Experimental: Administration of CC-92328
Drug: CC-92328

Primære egnethedskriterier

Inclusion Criteria: Participants must satisfy the following criteria to be enrolled in the study: 1. must understand and voluntarily sign an informed consent form (ICF) prior to any study-related assessments/procedures being conducted. 2. willing and able to adhere to the study visit schedule and other protocol requirements. 3. Participant is ≥ 18 years of age the time of signing the ICF. 4. Participant has a history of multiple myeloma (MM) with relapsed and/or refractory disease who have failed or who are ineligible or intolerant to available therapies that may provide clinical benefit. 5. Have documented disease progression on or within 12 months from the last dose of their last myeloma therapy. 6. Participant must have measurable disease. 7. Participant has an Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1. 8. Females of childbearing potential (FCBP) must commit to true abstinence from heterosexual contact or agree to use at least one method of highly effective contraception without interruption from screening to at least 9 weeks after the last dose of CC-92328 9. Males must practice true abstinence or agree to use a condom 10. FCBP and males must avoid conceiving from signing the ICF, while participating in the study, during dose interruptions, and for at least 9 weeks after the last dose of CC-92328. Exclusion Criteria: The presence of any of the following will exclude a participant from enrollment: 1. Participant has symptomatic central nervous system involvement of MM. 2. Participant had a prior autologous stem cell transplant ≤ 90 days prior to starting CC-92328. 3. Participant had a prior allogeneic stem cell transplant with either standard or reduced intensity conditioning ≤ 12 months prior to starting CC-92328. 4. Participant had prior systemic cancer-directed treatments or investigational modalities ≤ 5 half-lives or 4 weeks prior to starting CC-92328, whichever is shorter. 5. Participant is a pregnant or lactating female. 6. Participant received live virus vaccines within at least 4 weeks prior to starting study drug. 7. Participant has known active human immunodeficiency virus (HIV) infection. 8. Participant has active hepatitis B or C (HBV/HCV) infection. 9. Participant weight is ≤ 40 kg at screening.

Hvis du vil rapportere en bivirkning, kan du indberette direkte til Lægemiddelstyrelsen via hjemmesiden www.meldenbivirkning.dk
Vi anbefaler at du også kontakter BMS for at rapportere bivirkninger.
Bivirkninger og andre rapporterbare begivenheder er defineret her
Rapporter bivirkninger eller klager over produktkvalitet: Medicinsk information

466-DK-2200001